Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments

Characteristic Placebo n = 199 Armodafinil 150 mg/day n = 200
Age, years, mean (SD) 43.7 (11.6) 45.3 (11.3)
Males, n (%) 78 (39) 80 (40)
Race, n (%)   
 White 176 (88) 182 (91)
 Black 16 (8) 14 (7)
 Other 7 (4) 4 (2)
Weight, kg, mean (SD) 81.2 (17.5) 80.7 (17.5)
IDS-C30 total score, mean (SD) 43.3 (7.7) 42.4 (7.7)
QIDS-C16 total score, mean (SD) 16.8 (2.7) 16.1 (2.7)
CGI-S score, mean (SD) 4.6 (0.6) 4.6 (0.7)
GAF score, mean (SD) 54.8 (6.7) 53.6 (8.9)
C-SSRS   
Suicidal behavior, n (%)   
 Suicidal behavior, actual attempt 20 (10) 21 (11)
 Non-suicidal self-injurious behavior 7 (4) 6 (3)
 Interrupted attempt 3 (2) 2 (1)
 Aborted attempt 4 (2) 4 (2)
 Suicidal behavior 4 (2) 4 (2)
 Preparatory acts or behavior 5 (3) 6 (3)
Suicidal ideation, n (%)   
 Suicidal ideation, wish to be dead 27 (14) 37 (19)
 Non-specific active suicidal thoughts 16 (8) 24 (12)
 Any methods (no plan) without intent to act 12 (6) 20 (10)
 Some intent to act without specific plan 9 (5) 14 (7)
 Specific plan and intent 10 (5) 15 (8)
YMRS total score, mean (SD) 3.7 (2.1) 3.7 (2.2)
HAM-A total score, mean (SD) 12.6 (2.8) 12.5 (2.9)
ISI total score, mean (SD) 16.1 (5.2) 15.7 (5.5)
  1. CGI-S Clinical Global Impression of Severity of Illness, C-SSRS-SLV Columbia-Suicide Severity Rating Scale-Since Last Visit, GAF Global Assessment of Functioning, HAM-A Hamilton Anxiety Scale, IDS-C 30 30-Item Inventory of Depressive Symptomatology–Clinician-Rated, ISI Insomnia Severity Index, QIDS-C 16 16-Item Quick Inventory of Depressive Symptomatology–Clinician-Rated, SD standard deviation, YMRS Young Mania Rating Scale